Tenax Therapeutics Inc (TENX)

Currency in USD
1.8300
+0.1100(+6.40%)
Closed·
1.9000+0.0700(+3.83%)
·
Unusual trading volume
TENX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.70001.9200
52 wk Range
1.310019.4000
Key Statistics
Prev. Close
1.72
Open
1.7
Day's Range
1.7-1.92
52 wk Range
1.31-19.4
Volume
10.36M
Average Volume (3m)
2.92M
1-Year Change
-69.0355%
Book Value / Share
2.22
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TENX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.7000
Upside
+539.34%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Tenax Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Neutral
Moving Averages
Strong Sell

Analyst Ratings

7 Buy
3 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 11.7000
(+539.34% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Guggenheim
Buy4.00+118.58%40.00MaintainAug 11, 2026
Canaccord
Buy4.00+118.58%35.00MaintainAug 11, 2026
Evercore ISI
Hold---DowngradeAug 10, 2026
William Blair
Hold---DowngradeAug 10, 2026
Canaccord
Buy35.00+1,812.57%-New CoverageJul 28, 2026

Earnings

Latest Release
Jul 31, 2026
EPS / Forecast
-0.35 / -0.38
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

TENX Income Statement

Compare TENX to Peers and Sector

Metrics to compare
TENX
Peers
Sector
Relationship
P/E Ratio
−1.5x−1.9x−0.3x
PEG Ratio
0.03−0.020.00
Price/Book
0.9x2.4x2.6x
Price / LTM Sales
-8.4x3.1x
Upside (Analyst Target)
168.1%150.8%48.3%
Fair Value Upside
Unlock11.6%6.7%Unlock

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.20M7.34%7.23M
Other Institutional Investors
26.48M46.23%45.55M
Public Companies & Retail Investors
26.60M46.43%45.74M
Total
57.28M100.00%98.52M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC6.88%3,942,3736,781
Janus Henderson Group Ltd.3.17%1,815,4743,123

People Also Watch

344.08
IDCC
-2.09%
25.65
TNGX
+0.27%
108.220
ORKA
+0.76%
14.860
FIGS
+3.05%
21.99
VRDN
-3.89%

FAQ

What Is the Tenax Therapeutics (TENX) Stock Price Today?

The Tenax Therapeutics stock price today is 1.8300 USD.

What Stock Exchange Does Tenax Therapeutics Trade On?

Tenax Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Tenax Therapeutics?

The stock symbol for Tenax Therapeutics is "TENX."

What Is the Tenax Therapeutics Market Cap?

As of today, Tenax Therapeutics market cap is 105.9700M USD.

What Is Tenax Therapeutics's Earnings Per Share (TTM)?

The Tenax Therapeutics EPS (TTM) is -1.4673.

When Is the Next Tenax Therapeutics Earnings Date?

Tenax Therapeutics will release its next earnings report on Nov 18, 2026.

From a Technical Analysis Perspective, Is TENX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Tenax Therapeutics Stock Split?

Tenax Therapeutics has split 5 times.

How Many Employees Does Tenax Therapeutics Have?

Tenax Therapeutics has 15 employees.

What is the current trading status of Tenax Therapeutics (TENX)?

As of Aug 13, 2026, Tenax Therapeutics (TENX) is trading at a price of 1.8300 USD, with a previous close of 1.7200 USD. The stock has fluctuated within a day range of 1.7000 USD to 1.9200 USD, while its 52-week range spans from 1.3100 USD to 19.4000 USD.

What Is Tenax Therapeutics (TENX) Price Target According to Analysts?

The average 12-month price target for Tenax Therapeutics is 11.7000 USD, with a high estimate of 36 USD and a low estimate of 4 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +539.34% Upside potential.

What Is the TENX Premarket Price?

TENX's last pre-market stock price is 1.7100 USD. The pre-market share volume is 286,810.0000, and the stock has decreased by -0.0100, or -0.5800%.

What Is the TENX After Hours Price?

TENX's last after hours stock price is 1.9000 USD, the stock has decreased by 0.0700, or 3.8300%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.